Schroder Investment Management Group Collegium Pharmaceutical, Inc Transaction History

Schroder Investment Management Group

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$17.2 - $22.5 $785,214 - $1.03 Million	-45,652 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$17.5 - $21.35 $46,497 - $56,726	-2,657 Reduced 5.5%	45,652 $853,000
Q3 2021 Nov 12, 2021	SELL	$17.75 - $25.39 $305,211 - $436,581	-17,195 Reduced 26.25%	48,309 $954,000
Q2 2021 Aug 13, 2021	BUY	$21.74 - $25.28 $83,025 - $96,544	3,819 Added 6.19%	65,504 $1.55 Million
Q1 2021 May 17, 2021	SELL	$19.25 - $26.1 $258,893 - $351,018	-13,449 Reduced 17.9%	61,685 $1.46 Million
Q4 2020 Feb 16, 2021	SELL	$17.83 - $22.29 $260,086 - $325,144	-14,587 Reduced 16.26%	75,134 $1.51 Million
Q3 2020 Nov 13, 2020	SELL	$15.78 - $20.82 $158,352 - $208,928	-10,035 Reduced 10.06%	89,721 $1.9 Million
Q2 2020 Aug 13, 2020	BUY	$15.49 - $23.51 $364,402 - $553,072	23,525 Added 30.86%	99,756 $1.75 Million
Q1 2020 May 15, 2020	BUY	$13.89 - $25.45 $1.06 Million - $1.94 Million	76,231 New	76,231 $1.34 Million
Q3 2019 Nov 12, 2019	SELL	$10.16 - $13.28 $197,540 - $258,203	-19,443 Closed	0 $0
Q2 2019 Aug 08, 2019	BUY	$10.62 - $16.59 $206,484 - $322,559	19,443 New	19,443 $256,000

254

36.9M

100K

21.1K

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.12B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

Get notified when there are updates to the investment portfolio of Schroder Investment Management Group, based on Form 13F filings with the SEC.

Stay updated on Schroder Investment Management Group with notifications on news.